PMC7186327_01
Changes in tumor or metastasis size by computed tomography (CT) imaging before and after initiation of checkpoint blockade immunotherapy. Representative imaging showing decrease in size of colon mass for patient #1 (A,B) and liver metastasis for patient #2 (C,D) and patient #3 (E,F).
fonc-10-00581-g0002.jpg
PMC7186327_03_fonc-10-00581-g0002.jpg
F2
Within 5 months, these symptoms progressed to urinary retention, and imaging revealed a 5.5 cm sigmoid mass with invasion into the bladder and metastatic liver lesions (Figure 2E). Following an uncomplicated postoperative recovery, he was started on dual checkpoint blockade, nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), with a partial response of the liver metastases (Figure 2F).
PMC7186327_02
Changes in tumor or metastasis size by computed tomography (CT) imaging before and after initiation of checkpoint blockade immunotherapy. Representative imaging showing decrease in size of colon mass for patient #1 (A,B) and liver metastasis for patient #2 (C,D) and patient #3 (E,F).
fonc-10-00581-g0002.jpg
PMC7186327_03_fonc-10-00581-g0002.jpg
F2
Within 5 months, these symptoms progressed to urinary retention, and imaging revealed a 5.5 cm sigmoid mass with invasion into the bladder and metastatic liver lesions (Figure 2E). Following an uncomplicated postoperative recovery, he was started on dual checkpoint blockade, nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), with a partial response of the liver metastases (Figure 2F).
PMC7186327_03
Changes in tumor or metastasis size by computed tomography (CT) imaging before and after initiation of checkpoint blockade immunotherapy. Representative imaging showing decrease in size of colon mass for patient #1 (A,B) and liver metastasis for patient #2 (C,D) and patient #3 (E,F).
fonc-10-00581-g0002.jpg
PMC7186327_03_fonc-10-00581-g0002.jpg
F2
Within 5 months, these symptoms progressed to urinary retention, and imaging revealed a 5.5 cm sigmoid mass with invasion into the bladder and metastatic liver lesions (Figure 2E). Following an uncomplicated postoperative recovery, he was started on dual checkpoint blockade, nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), with a partial response of the liver metastases (Figure 2F).